Search research articles
Contact Us
Filters
Showing results (61-70 of 182) with videos related to
Page
of 19
Sort By:
Endocrine-Related Cancer
|
March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.
JAMA Network Open
|
October 27, 2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Satya Das, Liping Du, Cody L Lee, et al.
Science Advances
|
October 13, 2021
Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer
Ana Nikolic, Divya Singhal, Katrina Ellestad, et al.
Neuro-Oncology
|
May 9, 2017
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients
Christin Schmidt, Nil A Schubert, Sebastian Brabetz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 22, 2005
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein
Kevin C O'Connor, Heiner Appel, Lisa Bregoli, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
January 10, 2014
Neurog1 and Neurog2 control two waves of neuronal differentiation in the piriform cortex
Rajiv Dixit, Grey Wilkinson, Gonzalo I Cancino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Brian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
Jennifer A Chan, Keith Stuart, Craig C Earle, et al.
Neuro-Oncology
|
December 25, 2013
Lactate dehydrogenase A silencing in IDH mutant gliomas
Charles Chesnelong, Myriam M Chaumeil, Michael D Blough, et al.
Neuro-Oncology
|
December 15, 2011
An in vivo patient-derived model of endogenous IDH1-mutant glioma
H Artee Luchman, Owen D Stechishin, N Ha Dang, et al.
Page
of 19
Search research articles
Search
Showing results (61-70 of 182) with videos related to
Sort By:
Page
of 19
Endocrine-Related Cancer
|
March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.
JAMA Network Open
|
October 27, 2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Satya Das, Liping Du, Cody L Lee, et al.
Science Advances
|
October 13, 2021
Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer
Ana Nikolic, Divya Singhal, Katrina Ellestad, et al.
Neuro-Oncology
|
May 9, 2017
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients
Christin Schmidt, Nil A Schubert, Sebastian Brabetz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 22, 2005
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein
Kevin C O'Connor, Heiner Appel, Lisa Bregoli, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
January 10, 2014
Neurog1 and Neurog2 control two waves of neuronal differentiation in the piriform cortex
Rajiv Dixit, Grey Wilkinson, Gonzalo I Cancino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Brian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
Jennifer A Chan, Keith Stuart, Craig C Earle, et al.
Neuro-Oncology
|
December 25, 2013
Lactate dehydrogenase A silencing in IDH mutant gliomas
Charles Chesnelong, Myriam M Chaumeil, Michael D Blough, et al.
Neuro-Oncology
|
December 15, 2011
An in vivo patient-derived model of endogenous IDH1-mutant glioma
H Artee Luchman, Owen D Stechishin, N Ha Dang, et al.
Page
of 19